Sino Biopharmaceutical’s TQB2868 Shows Promise in Pancreatic Cancer Treatment

An update from Sino Biopharmaceutical ( (HK:1177) ) is now available.

Sino Biopharmaceutical Limited has announced promising preliminary results from a Phase II clinical study of its bi-functional fusion protein, TQB2868, combined with anlotinib and chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The study, presented at the 2025 ASCO Annual Meeting, showed significant improvements in objective remission and disease control rates compared to traditional chemotherapy regimens, with a favorable safety profile. This development could mark a significant breakthrough in pancreatic cancer treatment, potentially positioning TQB2868 as the first immune checkpoint inhibitor for first-line treatment, thereby improving patient survival and quality of life.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company in the biopharmaceutical industry, focusing on the development of innovative drugs. The company is involved in creating treatments for various diseases, with a market focus on oncology and other critical therapeutic areas.

Average Trading Volume: 103,024,004

Technical Sentiment Signal: Buy

Current Market Cap: HK$76.05B

For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.